Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | LDHA | P00338 | 2/20 | 0.34 |
| ▸ | LDHB | P07195 | 2/20 | 0.34 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7407270 | 1.00 | ALDH1A1 (0.38) | ALDH1A1MAPTPKMHSD17B10POLB | |
| SCHEMBL7452364 | 0.82 | ALDH1A1 (0.43) | ALDH1A1MAPTPOLBHPGDCYP3A4 | |
| SCHEMBL7408391 | 0.82 | ALDH1A1 (0.43) | ALDH1A1MAPTPOLBHPGDCYP3A4 | |
| SCHEMBL7604100 | 0.81 | ALDH1A1 (0.36) | ALDH1A1HSD17B10HPGDABCB1ALOX5 | |
| SCHEMBL7604096 | 0.81 | ALDH1A1 (0.36) | ALDH1A1HSD17B10HPGDABCB1ALOX5 | |
| SCHEMBL7404869 | 0.78 | TSHR (0.36) | ALDH1A1MAPTHSD17B10ABCB1TSHR | |
| SCHEMBL7454510 | 0.78 | TSHR (0.36) | ALDH1A1MAPTHSD17B10ABCB1TSHR | |
| SCHEMBL7609889 | 0.78 | ALDH1A1 (0.34) | ALDH1A1HSD17B10HPGDABCB1CYP3A4 | |
| SCHEMBL7412352 | 0.78 | ALDH1A1 (0.34) | ALDH1A1HSD17B10HPGDABCB1CYP3A4 | |
| SCHEMBL7400452 | 0.77 | ABCB1 (0.41) | ALDH1A1MAPTPKMHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6174915-B1 | FOR TREATING MAMMALIAN DISEASE CONDITION MEDIATED BY METALLOPROTEINASE ACTIVITY | AGOURON PHARMACEUTICALS, INC. | 2001-01-16 | — | — | US | claimed |
| US-6495699-B2 | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | AGOURON PHARMACEUTICALS INC. | 2002-12-17 | — | — | US | disclosed |
| US-20020019429-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use | BENDER STEVEN L (US) | 2002-02-14 | — | — | US | disclosed |
| US-6306892-B1 | ENZYME INHIBITORS HETEROCYCLIC AMIDES | AGOURON PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6174915-B1 | FOR TREATING MAMMALIAN DISEASE CONDITION MEDIATED BY METALLOPROTEINASE ACTIVITY | AGOURON PHARMACEUTICALS, INC. | 2001-01-16 | — | — | US | disclosed |
| US-6008243-A | AN ENZYME INHIBITOR FOR PREVENTING THE DEGRADATION AND REMODELING OF CONNECTIVE TISSUES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0937042-A1 | HETEROARYL SUCCINAMIDES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998017643-A1 | HETEROARYL SUCCINAMIDES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019429-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use | MMP9, MMP2, MMP3 | ALDH1A1 733/4885MAPT 4640/4885PKM 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.